StockMarketWire.com - Clinical diagnostics group Renalytix said it formed a collaboration with University Medical Center Groningen in the Netherlands.

The pair had agreed to evaluate the company's technology across over 3,500 patients with type two diabetes.

The study would assess how effectively the technology identified patients with fast-progressing kidney disease.

The company's KidneyIntelX test would be performed at multiple time points on over 9,000 patient samples.


At 9:03am: [LON:RENX] share price was +5p at 175p



Story provided by StockMarketWire.com